Jazz Pharmaceuticals Reports 2025 Financial Results and Provides 2026 Guidance

Details

The company also provided guidance for 2026, expecting total revenues between $4.25 and $4.50 billion. Key product performances included Xywav net product sales of $1.7 billion with 12% growth and Epidiolex net product sales of $1.1 billion with 9% growth. The company also expects to complete the sBLA submission for zanidatamab in 1Q26 under RTOR for HER2+ 1L GEA.

Items reported

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc is a global biopharmaceutical company that focuses on developing life-changing medicines for patients in various therapeutic areas. The company's primary function is to research, manufacture, and market drugs that address unmet medical needs, particularly in the fields of neuroscience, oncology, and sleep medicine. Jazz Pharmaceuticals has gained prominence for its innovative products such as Xyrem, used for treating narcolepsy, and Vyxeos, a treatment for certain types of leukemia. Headquartered in Dublin, Ireland, the company operates extensively across North America and Europe, working to advance scientific research in pharmaceuticals. By prioritizing patient care and survival, Jazz Pharmaceuticals plays a significant role in the pharmaceutical industry with its commitment to developing novel therapies. Moreover, the company's strategic collaborations and acquisitions enable it to expand its product portfolio and impact the healthcare sector positively. Jazz Pharmaceuticals continues to be a key player in transforming patient care for complex conditions.